行情

ONCS

ONCS

OncoSec医疗
NASDAQ

实时行情|Nasdaq Last Sale

1.850
-0.030
-1.60%
休市 16:00 01/24 EST
开盘
1.930
昨收
1.880
最高
1.980
最低
1.810
成交量
8.06万
成交额
--
52周最高
9.46
52周最低
1.600
市值
1,981.48万
市盈率(TTM)
-0.4576
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONCS 新闻

  • 微博2020让红包飞集卡玩出新高度 超14亿人次参与
  • 新浪科技.1小时前
  • 玩游戏了解流行病?单机游戏“瘟疫公司”多国畅销
  • 新京报网.2小时前
  • 携程升级重大灾害保障金至2亿
  • 36氪.3小时前
  • 新东方向湖北省红十字会捐款2000万元
  • 新浪科技.5小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

ONCS 简况

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
展开

Webull提供OncoSec Medical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。